Kanmaz Kutman, Hayriye GözdeSiyah Bilgin, BetülBüyüktiryaki, MehmetKadıoğlu Şimşek, GülsümÜstünyurt, ZeynepCanpolat, Fuat Emre2026-01-292026-01-292025Kanmaz Kutman, H. G., Siyah Bilgin, B., Büyüktiryaki, M., Kadıoğlu Şimşek, G., Üstünyurt, Z. ve Canpolat, F. E. (2025). Risk factors in addition to short and long-term outcomes with thin catheter surfactant administration failure in preterm infants: a retrospective analysis. Journal of Paediatrics and Child Health, 61(3), 451-456. http://dx.doi.org/10.1111/jpc.167771034-48101440-1754http://dx.doi.org/10.1111/jpc.16777https://hdl.handle.net/20.500.12511/13392Objective: To evaluate the incidence of thin catheter surfactant administration (TCA) failure and compare short and long-term neonatal outcomes who failed TCA or did not. Design: Single-center retrospective cohort study. Infants between 25 and 30 weeks of gestational age with respiratory distress syndrome and receiving 200 mg/kg poractant alfa via thin catheter administration were included. TCA failure was defined as the need for early mechanical ventilation (< 72 h). Infants were divided into two groups those who failed TCA or those who did not. Results: The TCA failure rate was 24.6%. Initial oxygen requirement (0.39% vs. 0.36%) and the number of small for gestational age infants were significantly higher in the TCA failure group (15% vs. 7.9%). Infants who failed TCA had a higher pneumothorax (6.7% vs. 1.1%, p = 0.03), BPD (15% vs.5.5%, p = 0.02), late-onset sepsis (36.7% vs. 18%, p = 0.04), retinopathy of prematurity rates (11.7% vs. 3.3%, p = 0.02) and an increased duration of respiratory support. However, Bayley Scales of Infant Development II scores were comparable between groups at 18 and 26 months of corrected age. Conclusion: Infants who fail TCA are at increased risk for short-term complications despite favourable long-term neurodevelopmental outcomes. Identifying infants at risk of TCA failure may help early prevention of morbidities and individualise their management.eninfo:eu-repo/semantics/openAccessBiological ProductsInfantNewbornPrematureRespiratory Distress SyndromeRisk FactorTreatment FailureArticle61345145610.1111/jpc.16777Q3WOS:0013964478000012-s2.0-8521466233339800857Q2